
    
      This study will be conducted at a single study center in Parexel Early Phase Clinical Unit
      London.

      A total of 12 healthy male and female volunteers (of non-childbearing potential) will be
      randomized.

      The study will comprise:

        -  A screening period of maximum 28 days

        -  Five treatment periods

        -  There will be a washout period of 3 to 6 days between dose administrations

        -  Follow-up visit, 5 to 7 days after last dose

      Each volunteer will be involved in the study for between 7 and 9 weeks. The volunteers will
      be admitted to the Unit on the day before first dosing in Treatment Period 1 until at least
      72 hours after last dosing in Treatment Period 5.
    
  